GlaxoSmithKline presents the PRIMA study for first-line ovarian cancer
Category: #health  | By Mateen Dalal  | Date: 2019-09-30 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GlaxoSmithKline presents the PRIMA study for first-line ovarian cancer

The treatment graph for one of the most fatal ailments of the 21st century, the dreaded ‘cancer’, seems to be on the verge of witnessing yet another variable addition. In what may seem as yet another stupendous effort by healthcare companies and the like to cure one of the deadliest diseases known to mankind, the results for yet another clinical study have been announced by a prominent organization.

Recently, biopharma company Zai Lab Limited made it to the headlines by announcing the results of its partner, GlaxoSmithKline’s, PRIMA. Incidentally, PRIMA is a randomized, double-blind, placebo-controlled Phase 3 study of Zejula (niraparib) as maintenance therapy in women who are suffering from first-line ovarian cancer, following a response to platinum-based chemotherapy. According to reports, there is reduced 38% disease progression risk or death in the overall population because of niraparib treatment.

PRIMA is the first study which demonstrates, a PARP inhibitor that significantly improves PFS, regardless of biomarker status.

There is a meaningful reduction in risk of progression in the women who are suffering from BRCA mutation tumors, HR-deficient BRCA wild type tumors, and HR-proficient tumors.

This study registered response of patients to first-line platinum-based chemotherapy treatment which also includes patients with a high risk of disease progression.

In an interim assessment of overall survival (OS), niraparib also showed an encouraging improvement in overall survival relative to placebo. A pre-scheduled interim analysis of overall analysis statically favored niraparib in the overall population. On niraparib, 91% of patients were alive at 24 months against 85% for placebo, in HR-deficient group.

However, the authenticity of this data is not fully known. The analysis also showed 81% of women on niraparib were alive at 24 months against 59% of women receiving placebo, in HR deficient group.

Currently, Niraparib is not approved as a treatment for first-line ovarian cancer. GSK will be sharing these data with the relevant health authorities.

Dr. Hal Barron, President, and Chief Scientific Officer R&D stated that Ovarian cancer is the eighth most commonly occurring disease in women. PRIMA is a landmark study in this context, as the company believes that this data has the potential to change ovarian cancer treatment landscape.

Source Credit - https://zailab.gcs-web.com/news-releases/news-release-details/phase-3-prima-trial-zejular-niraparib-first-stud  y-show-parp-0

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

Russia-Ukraine war puts UK fish & chips industry in severe jeopardy

By Mateen Dalal

The on-going conflict between Russia and Ukraine has adversely affected the fish and chips industry in the United Kingdom, driving the closure of centuries-old shops, sharp price hikes, and change in menus. The National Federation of Fish Friers (...

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

U.S Govt. pledges $3.16 bn funding to boost EV battery manufacturing

By Mateen Dalal

The U.S. Department of Energy (DOE) has reportedly announced funds of $3.16 billion from President Joe Biden’s ‘Bipartisan Infrastructure Law’ for bolstering the domestic battery manufacturing and supply chain and creating more jobs...

Ammann rolls out new ADS technology to analyze jobsite compaction data

Ammann rolls out new ADS technology to analyze jobsite compaction data

By Mateen Dalal

Swiss mechanical engineering company Ammann has reportedly introduced a new ADS (Ammann Documentation System) technology. This new technology is geared towards capturing and further analyzing jobsite compaction data, which can lead to improved qualit...